INSULIN MONO LENTE S

 

StockNo	Product description
EB028044502	INSULIN MONO LENTE S VIAL 10 ML/400 IU
EB028044512	INSULIN MONO LENTE S VIAL 10 ML/800 IU
EB028044513	INSULIN MONO LENTE S VIAL 10 ML/1000 IU

 

COMPOSITION:
A mixture of 30 % amorphous suspension and 70 % crystal suspension of porcine zinc-insulin, 40 IU/ml.
The preparation is from highly purified insulin substance produced according to highly effective chromatographic methods.

ACTION:
Insulin is a polypeptide hormone, which participates in the regulation of carbohydrate, fat and protein metabolism. It increases the transport of glucose through the plasma membranes of cells, muscles, heart, fatty tissue and WBC, stimulates its oxidation and increases the synthesis and the cumulation of glycogen in the liver and muscles. Insulin stimulates the inclusion of the fatty acids into Kreb's cycle, increases the triglyceride depots in fatty tissue and decreases the formation of keto-bodies. The changes in carbohydrate metabolism are characterized by prevalence of the anabolic processes. Insulin realizes its numerous effects by binding to the specific insulin receptors which have a membrane localization.

PHARMACOKINETICS:
Insulin mono Lente S possesses a rapidly occurring but prolonged hypoglycemic action. The effect comes within the first hour after subcutaneous application, reaches its maximum after 190 min to 4 h, and lasts 16-18 h, depending on the individual properties of the carbohydrate metabolism of the patient.

INDICATIONS:
Insulin-dependent diabetes mellitus with different gravity. In cases of allergy or resistance to bovine insulin preparation.

CONTRAINDICATIONS:
Absolute contraindications are not known. The heavy Insulin allergy of "immediate type" is relative contraindication.
The preparation should be applied cautiously to patients with diseases accompanied by hypoglycemia.

SIDE EFFECTS:
Lipodystrophy or transitory edema at the place of application, if the place of injection is not changed. Allergic reaction of "immediate type" (erythema, eruption, itching) may be observed in extremely rare cases.

PRECAUTIONS:
Hypoglycemia may occur during treatment as a result of heavy physical loads, in case of irregular meals, vomiting, nephropathy in advanced stage, decreases function of the thyroid and pituitary glands, as well as after application of higher doses or increased sensitivity towards insulin. Each patient must be informed about the main symptoms of hypoglycemia - headache, strong perspiration, sleep disturbances, speech and vision disturbances, and psychic disturbances with depressive character up to loss of consciousness.
In case the hypoglycemia, the patient must take immediately sweetened tea or sugar. The hypoglycemic coma is treated with 40% glucose solution i.v., in severe cases of 1 ml of 0.1% solution of adrenalin of glucagon may be applied subcutaneously.

DOSAGE AND ADMINISTRATION:
The treatment with Insulin depot preparations must always begin under doctor's control, based on the data of the blood sugar profile and the calculations of the carbohydrate balance. The preparation is applied subcutaneously, the daily dose of each patient being determined individually. Before use, the vial must be shaken thoroughly and the suspension should be injected immediately after aspiration.
Different Insulin preparations should not be mixed in one syringe because of the different pH of the solutions.

MEDICINAL FORM AND PACKAGE:
Vials of 10 ml/400, 800 or 1000 IU - in packs of 1 to 5.

STORAGE:
At temperature from 2 to 8° C.
DO NOT FREEZE!

EXPIRY:
2 (two) years.